What types of cancer can myo-inositol (MI) and D-chiro-inositol (DCI) help prevent?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lung Cancer Prevention by Myo-Inositol

Myo-inositol (MI) has been investigated specifically for lung cancer chemoprevention, particularly in smokers at high risk, while D-chiro-inositol (DCI) has not been studied for cancer prevention.

Evidence for Myo-Inositol in Lung Cancer Prevention

Mechanism of Action

  • Myo-inositol inhibits the PI3K pathway that is activated in bronchial epithelial cells of smokers with dysplasia, which correlates with regression of bronchial dysplasia 1
  • Animal studies demonstrate that myo-inositol inhibits carcinogenesis by 40-50% in both the induction and postinitiation phases 1
  • When combined with budesonide, efficacy increases to up to 80% in preclinical models 1

Clinical Investigation Status

  • The American College of Chest Physicians guidelines (2013) describe myo-inositol as having low toxicity and promising preclinical and phase 1 data 1
  • An ongoing phase 2b randomized placebo-controlled trial is evaluating myo-inositol's chemopreventive effect in smokers with bronchial dysplasia at high risk of lung cancer, including those at risk for second primary lung cancer 1

Target Population

  • Smokers at high risk for lung cancer 1
  • Patients with bronchial dysplasia 1
  • Individuals at risk for second primary lung cancer 1

D-Chiro-Inositol and Cancer Prevention

D-chiro-inositol has NOT been studied or recommended for any type of cancer prevention. The available evidence for DCI focuses exclusively on metabolic conditions:

  • DCI is used clinically for polycystic ovary syndrome (PCOS) and insulin resistance 2, 3, 4
  • DCI acts by improving insulin signaling and downregulating aromatase expression 3
  • No cancer prevention studies exist for DCI in the reviewed literature 2, 3, 5, 4, 6

Important Clinical Caveats

  • Myo-inositol for lung cancer prevention remains investigational and is not yet recommended for routine clinical use outside of well-designed clinical trials 1
  • The evidence base is limited to preclinical studies and early-phase clinical trials 1
  • Myo-inositol is found naturally in whole grains, seeds, and fruits and is an essential nutrient required by human cells for growth and survival 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The use of D-chiro-Inositol in clinical practice.

European review for medical and pharmacological sciences, 2021

Research

Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.